DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

BLA 103362/S-5237

SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING COMMITMENTS

Sanofi-aventis U.S. LLC
Attention: Sunil Gupta, MD
Associate Vice-President, Global Regulatory Affairs
500 Kendall Street
Cambridge, MA 02142

Dear Dr. Gupta:

Please refer to your Supplemental Biologics License Application (sBLA), dated August 10, 2016, received August 10, 2016, and your amendments, submitted under section 351(a) of the Public Health Service Act for Leukine® (sargramostim) Injection, 250 mcg, 500 mcg.

This Prior Approval supplemental biologics application provides for revisions to the prescribing information based on evaluation of immunogenicity in subjects enrolled in studies of Leukine.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the prescribing information) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING COMMITMENTS

We have received your submissions dated August 27, 2015 and March 11, 2016 reporting on the following postmarketing commitments listed in the September 22, 2003 approval letter for BLA 103362/1077 and your August 10, 2016, submission containing the final report.

PMC 2391-2 To submit a report of the immunogenicity evaluation of all subjects enrolled in studies of Sargramostim as identified in your facsimile transmission of September 22, 2003. Specifically, the report will include the primary results of 214 patients who received a (b) (4) lyophilized formulation of Sargramostim in clinical studies conducted by Berlex and information from published literature reports. This information will be submitted by April 30, 2004.

PMC 2391-7 To submit revised labeling, based on the data described above, which accurately reflects the immune response to our product by April 30, 2004. If the data are inadequate to characterize the immune response to Sargramostim, Berlex will indicate as such and provide a plan for characterizing the immune response to the product when used in accordance with the approved labeling by April 30, 2004.

We have reviewed your submissions and conclude that the above commitments were fulfilled.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our September 22, 2003, letter.

We remind you that there are postmarketing commitments listed in the December 4, 2009 and March 14, 2012 approval letters that are still open.

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 601.12(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety

information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Ms. Diane Leaman, Safety Regulatory Project Manager, at (301) 796-1424.

Sincerely,

{See appended electronic signature page}

Barry W. Miller
Acting Deputy Director for Safety
Division of Hematology Products
Office of Hematology Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BARRY W MILLER
02/10/2017